Risultati per: Percorsi personalizzati contro il cancro legati al gene BRCA

Il 70% dei pazienti oncologici trova informazioni errate sui social

Circulation, Volume 149, Issue 13, Page e1026-e1026, March 26, 2024.

Gli oncologi, l’intervento tempestivo aiuta la cura. La chemioterapia probabilmente è preventiva per evitare le recidive

New England Journal of Medicine, Volume 390, Issue 12, Page 1092-1104, March 2024.

Hypertension is the number one cause of disability-adjusted life-years worldwide and the world’s leading risk factor for burden of disease and death. It is the most important risk factor for stroke and congestive heart failure, a major cause of kidney failure, and plays an important role in other forms of cardiovascular disease, including atherosclerosis and coronary artery disease. Hypertension affects approximately 48% of adults in the US and nearly 1 billion adults worldwide. Control of hypertension worldwide is dismal, and even in the US only 25% of adults achieve goal blood pressure (BP). BP elevations above 115/75 mm Hg are associated in a continuous fashion with the risk of fatal stroke, ischemic heart disease, and noncardiac vascular disease, and each increase of 20 mm Hg systolic BP or 10 mm Hg diastolic BP doubles the risk of a fatal cardiovascular event. Thus, achieving goal BP is critical to improve outcomes of patients with hypertension, and risk of CVD is significantly reduced by antihypertensive therapy. A 10 mm Hg lower systolic or 5 mm Hg lower diastolic BP results in a 40% reduction in stroke risk and a 30% reduction in ischemic heart disease risk. Control of BP to the therapeutic goal improves outcomes more than treating other chronic conditions, such as dyslipidemia.

Al Tiget di Milano è stata dimostrata per la prima volta in vivo l’efficacia del silenziamento epigenetico, da effettuare una sola volta nella vita. Lo studio, pubblicato su Nature, potrebbe servire anche per altre malattie

Al Tiget di Milano è stata dimostrata per la prima volta in vivo l’efficacia del silenziamento epigenetico, da effettuare una sola volta nella vita. Lo studio, pubblicato su Nature, potrebbe servire anche per altre malattie

Il convegno “Per Amarla-Percorso e Rete Mammella Regione Lazio”

Gli animali si espongono alle radiazioni cancerogene mentre vagano per la città ucraina, abbandonata dopo un incidente nucleare nel 1986. Secondo i ricercatori di Priceton parte delle loro informazioni genetiche sembrano resistenti all’aumento del rischio di malattia

Miglioramento della sopravvivenza a 5 anni se il tumore è in fase precoce

Il rischio di morte è 4 volte più alto, vaccino potrebbe ridurlo

New England Journal of Medicine, Volume 390, Issue 6, Page 530-535, February 2024.

Comunicato del 04/02/2024 n°7

Stroke, Volume 55, Issue Suppl_1, Page ATP233-ATP233, February 1, 2024. Introduction:Breast cancer susceptibility gene (BRCA) mutations are well-known causes of systemic cancers. We have previously identified that those with BRCA mutations have a higher likelihood of cerebral microbleeds (CMBs) on brain MRI compared to BRCA wildtype. We aimed to confirm our prior findings in a subsequent cohort.Methods:We performed a single-center retrospective review of all individuals with a confirmed diagnosis of BRCA 1 or 2 mutation and a standard-of-care brain MRI. All individuals were ≥ 18 years old, without intracranial radiation, cerebral metastases, or other cerebral processes which may impact interpretation. Our comparative cohort were individuals with breast cancer who have a genetically confirmed BRCA wildtype status. The primary outcome was the presence of CMBs, defined by consensus criteria. Standard descriptive techniques were used. Likelihood ratios were calculated by binary logistic regression and adjusted for significant variables.Results:We identified 49 individuals who met inclusion criteria: 15 with BRCA mutation and 34 with BRCA wildtype. Only one patient was with aspirin use in the BRCA mutation cohort. All cancers were of breast origin with 4 BRCA mutations patients with cancer staging ≥ 3 compared with 14 in the BRCA wildtype cohort. Chemotherapy rates did not differ. Patients with BRCA were younger, less often with hyperlipidemia, and more commonly had CMBs, Table 1. The presence of BRCA mutation trended towards higher odds of having a CMB (OR 5.8, 95%CI 0.93 – 36.16,p= 0.059) after adjustment for age and hyperlipidemia.Conclusion:We found that CMBs were more common in the BRCA mutation cohort, with a trend towards a 5-fold higher likelihood in the regression analysis. While underpowered, our findings support prior data highlighting this association. Further studies with larger sample sizes are warranted.